MUC1 and breast carcinoma: From an immunotherapeutic setting, a 15‐year follow‐up on clinical trials employing oxidized mannan–MUC1 revealed that treatment with the oxidized mannan–MUC1 significantly reduced the recurrence rate in stage II breast cancer patients [89].